Switch theme
Sign up to access all valuation multiples
Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.
1994
1
LTM Revenue n/a
LTM EBITDA n/a
$42.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vivos has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Vivos achieved revenue of $28K and an EBITDA of -$2.6M.
Vivos expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vivos valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $20K | $28K | XXX | XXX | XXX |
| Gross Profit | $8K | -$6K | XXX | XXX | XXX |
| Gross Margin | 40% | -22% | XXX | XXX | XXX |
| EBITDA | -$2.8M | -$2.6M | XXX | XXX | XXX |
| EBITDA Margin | -14324% | -9303% | XXX | XXX | XXX |
| Net Profit | -$2.5M | -$2.9M | XXX | XXX | XXX |
| Net Margin | -12667% | -10340% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 24, 2025, Vivos's stock price is $0.
Vivos has current market cap of $44.4M, and EV of $42.2M.
See Vivos trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $42.2M | $44.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 24, 2025, Vivos has market cap of $44.4M and EV of $42.2M.
Vivos's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Vivos's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Vivos and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $42.2M | XXX | XXX | XXX |
| EV/Revenue | 1508.1x | XXX | XXX | XXX |
| EV/EBITDA | -16.2x | XXX | XXX | XXX |
| P/E | -15.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -25.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVivos's NTM/LTM revenue growth is n/a
Vivos's revenue per employee for the last fiscal year averaged $28K, while opex per employee averaged $2.6M for the same period.
Over next 12 months, Vivos's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Vivos's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Vivos and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 44% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -9303% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -7% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $28K | XXX | XXX | XXX | XXX |
| Opex per Employee | $2.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 8133% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1160% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 9292% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vivos acquired XXX companies to date.
Last acquisition by Vivos was XXXXXXXX, XXXXX XXXXX XXXXXX . Vivos acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Vivos founded? | Vivos was founded in 1994. |
| Where is Vivos headquartered? | Vivos is headquartered in United States of America. |
| How many employees does Vivos have? | As of today, Vivos has 1 employees. |
| Is Vivos publicy listed? | Yes, Vivos is a public company listed on PINX. |
| What is the stock symbol of Vivos? | Vivos trades under RDGL ticker. |
| Who are competitors of Vivos? | Similar companies to Vivos include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Vivos? | Vivos's current market cap is $44.4M |
| What is the current revenue growth of Vivos? | Vivos revenue growth between 2023 and 2024 was 44%. |
| Is Vivos profitable? | Yes, Vivos is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
